Tissue Chips in Space Accelerate Aging Research
Space is no longer just a frontier for exploration — it has become one of the most powerful laboratories for understanding how the human body ages. Through NASA’s Tissue Chips in Space 2.0 initiative, researchers are leveraging the unique conditions of microgravity to accelerate discoveries in aging science, disease modeling, and drug development.
What Is Microgravity and Why It Matters
During spaceflight, astronauts experience microgravity — a state of diminished or near-zero gravity compared to Earth. This environment causes the human body to age at an accelerated rate, mirroring conditions such as cardiac dysfunction, immunosenescence (immune system decline), osteoporosis (bone density loss), and fibrosis (excessive buildup of cellular matrix). On Earth, studying these conditions takes years. In space, the accelerated pace of aging allows researchers to model disease progression and identify new therapies far more quickly. The International Space Station National Laboratory (ISS-NL) provides an unparalleled setting for this cutting-edge biomedical research.
Understanding Microphysiological Systems (MPS)
Microphysiological systems (MPS) are bioengineered microfluidic devices — tiny fluid-channel platforms seeded with human cells and tissues — designed to mimic the structure and function of real organ systems. Compared to traditional cell cultures and animal models, MPS offer a significantly more accurate representation of the human body. They are increasingly essential tools for drug discovery, regulatory safety testing, efficacy evaluation, and the advancement of precision medicine. Their ability to replicate human biology makes them ideal candidates for spaceflight experiments.
Tissue Chips in Space 2.0 Program Overview
Building on the original Tissue Chips in Space initiative launched in 2016, Tissue Chips in Space 2.0 focuses on refining multiorgan MPS technology to better model whole-body physiology. In 2025, the National Institutes of Health (NIH) awarded six research grants through a two-phase cooperative agreement. In Phase 1, researchers design and validate MPS that accurately replicate complex organ systems both on Earth and in space. In Phase 2, teams with successful chip models are selected to send their MPS to the ISS-NL in low Earth orbit, where microgravity conditions will reveal new insights into human aging and disease.
2025 Awarded Research Projects
Brain–Muscle MPS for Aging and Extracellular Vesicles Led by researchers at the University of Florida and Brigham and Women’s Hospital, this project investigates how communication between the brain and muscles — mediated by extracellular vesicles — contributes to age-related diseases like Alzheimer’s and Parkinson’s.
Cardiovascular Aging With AI and 3D Organoids Stanford University and the University of Pittsburgh are studying how microgravity affects heart function, metabolism, and inflammation. Using artificial intelligence and 3D organoids, the team aims to identify therapeutic candidates for heart disease and improve long-term astronaut health.
Reproductive Health, Aging, and Disease in Women CFD Research Corporation is developing an organ-on-chip model combining female reproductive cell types and hormone exposure to uncover mechanisms of uterine aging and identify potential treatments using AI and machine learning.
Inflammaging in Heart, Gut, and Brain Chip Models Cedars-Sinai Medical Center researchers are exploring how the accumulation of senescent cells and damaged proteins triggers chronic inflammation — known as inflammaging — in the heart, gut, and brain, while testing compounds that could reverse cellular aging.
Neurological Disorders and Brain-Heart Crosstalk The University of Alabama at Birmingham team is studying the link between Alzheimer’s disease and cardiovascular health in a microgravity environment, with a focus on senolytic compounds — therapies that selectively eliminate aging cells.
Aging Alveolar Lung Model in Microgravity Researchers are building a 3D lung model incorporating multiple cell types — epithelial, endothelial, fibroblast, and immune — to study fibrosis and age-related lung disease, offering a powerful platform for discovering new respiratory therapies.
Why This Research Matters for Human Health
The insights generated by Tissue Chips in Space 2.0 extend far beyond space exploration. By identifying clinically relevant disease markers, pinpointing mechanisms of disease progression, and testing novel therapies in a uniquely accelerated aging environment, this research could establish a critical preclinical framework to guide clinical trials for aging-related conditions on Earth. It also directly supports astronaut health and safety during long-duration missions, including deep space exploration.
As Dmitriy Krepkiy, Ph.D., Program Officer at NCATS’ Office of Special Initiatives, noted, the program enables unprecedented experiments in microgravity that are impossible to replicate on Earth — driving advances in microphysiological technologies and expanding access to tissue chip platforms for the broader research community.
